08/04/2025 15:00
LambdaTest and Lab49 Forge a Strategic Partnership to Advance AI-driven Software Testing in Financial Services

LambdaTest, a GenAI-native quality engineering platform, has entered a strategic partnership with Lab49, a leading consultancy specializing in strategy, design, and technology for capital markets, to help financial services organizations modernize their software testing and drive digital innovation. The partnership brings together LambdaTest’s next-generation AI-native test automation capabilities and Lab49’s proven track record of delivering enterprise-grade solutions to the world’s leading ...

07/01/2025 07:00
Lyten Acquires Europe’s Largest Battery Energy Storage Systems Manufacturing Operation from Northvolt

Lyten, the supermaterial applications company and global leader in lithium-sulfur batteries, announced today the acquisition of Northvolt’s Dwa ESS operations in Gdansk, Poland, a 25,000 square meter (270,000 sq ft) battery energy storage systems (BESS) manufacturing and R&D facility. Northvolt Dwa ESS is the largest BESS manufacturing facility in Europe and was part of Northvolt Systems. The financial terms of the acquisition are not being released by either party. This press release feat...

07/01/2025 07:00
Cargill Sets a New Global Benchmark for More Sustainable Cocoa Supply Chains

Cargill today announced a transformation of its global cocoa supply chain, unveiling a series of interconnected investments that reduce carbon emissions, eliminate waste, and boost efficiency from cocoa origin countries in West Africa to processing hubs in Europe. The company’s upgrades span renewable energy, circular logistics, and smart infrastructure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250701468198/en/Cargill today an...

07/10/2025 15:29
Lookout Survey Reveals Critical Gaps in Security Leaders' Confidence and the Actual Vulnerability of Their Organizations

A new global survey by Lookout, Inc., the leader in mobile endpoint security, today unveiled concerning insights into the state of mobile cybersecurity preparedness, revealing a significant gap between security leaders' confidence and the actual vulnerability of their organizations. The survey of more than 700 security leaders globally exposes a pervasive overconfidence in employees' ability to detect modern mobile-centric threats, leaving businesses significantly more exposed than they realize...

07/22/2025 08:06
Cisco Takes Licence to the Sisvel Wi-Fi 6 Patent Pool

Cisco Systems, Inc has become the latest licensee of the Sisvel Wi-Fi 6 patent pool programme. The deal, which was reached on an amicable basis, provides Cisco with one-stop access to close to 2,000 patents (245 patent families) recognised to date, through the pool’s process of independent patent evaluations, as essential to the 802.11ax Wi-Fi 6 standard. Cisco is the worldwide technology leader that is revolutionising the way organisations connect and protect in the AI era. It is a global ...

07/22/2025 08:00
Fresha Enhances Customer Engagement with RCS for Business Powered by Twilio and Google

Twilio (NYSE: TWLO), the customer engagement platform that drives real-time, personalised experiences for today’s leading brands, today announced that Fresha, a leading booking platform for the beauty and wellness industry, is building deeper customer trust and driving significant business growth by adopting Rich Communication Services (RCS) messaging, powered by Twilio and Google. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/202507...

07/28/2025 11:15
Filgotinib Shows Positive Topline Results Across Full Spectrum of Axial Spondyloarthritis in OLINGUITO Phase 3 Study

Alfasigma S.p.A today announced positive topline results from the OLINGUITO Phase 3 clinical trial (NCT05785611; Eudra CT 2022-501354-10-01),i evaluating filgotinib (marketed as Jyseleca® in approved indications) to treat adult patients with active axial spondyloarthritis (axSpA). Filgotinib, an oral, once-daily JAK1 preferential inhibitor, met the primary endpoint in the OLINGUITO Phase 3 clinical trial in active axSpA. Efficacy was demonstrated across the full spectrum of axSpA, including b...